Comment on: "Clinical Pharmacokinetics of Atypical Antipsychotics: An Update"/Reply

[...]the active metabolite didesmethyl-CRP (DDCRP) is more abundant at steady state than CRP. Conflict of interest Antonia Periclou and Todd Riccobene are employees of Allergan plc. and Margit Kapás and István Laszlovszky are employees of Gedeon Richter Plc. Open Access This article is distributed u...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacokinetics 2019-09, Vol.58 (9), p.1215-1218
Main Authors: Periclou, Antonia, Riccobene, Todd, Kapás, Margit, Laszlovszky, István, Mauri, Massimo Carlo
Format: Article
Language:English
Subjects:
Conflicts of interest
Drug dosages
Funding
Metabolites
Pharmaceutical industry
Pharmacokinetics
Pharmacology
Plasma
Psychotropic drugs
Schizophrenia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the active metabolite didesmethyl-CRP (DDCRP) is more abundant at steady state than CRP. Conflict of interest Antonia Periclou and Todd Riccobene are employees of Allergan plc. and Margit Kapás and István Laszlovszky are employees of Gedeon Richter Plc. Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. First of all, I should underline that the indications of a drug reported in the product labelling or by the industry can be different from, or simply don't have to coincide with, data in the literature.
ISSN:0312-5963
1179-1926
DOI:10.1007/s40262-019-00795-9